Role and mechanism of action of sclerostin in bone

发布时间：2025-07-24 17:12

'Making a business presentation in front of an audience'，要有自信 #生活技巧# #职场沟通技巧# #商务英语#

Review

Role and mechanism of action of sclerostin in bone

Jesus Delgado-Calle et al. Bone. 2017 Mar.

Abstract

After discovering that lack of Sost/sclerostin expression is the cause of the high bone mass human syndromes Van Buchem disease and sclerosteosis, extensive animal experimentation and clinical studies demonstrated that sclerostin plays a critical role in bone homeostasis and that its deficiency or pharmacological neutralization increases bone formation. Dysregulation of sclerostin expression also underlies the pathophysiology of skeletal disorders characterized by loss of bone mass, as well as the damaging effects of some cancers in bone. Thus, sclerostin has quickly become a promising molecular target for the treatment of osteoporosis and other skeletal diseases, and beneficial skeletal outcomes are observed in animal studies and clinical trials using neutralizing antibodies against sclerostin. However, the anabolic effect of blocking sclerostin decreases with time, bone mass accrual is also accompanied by anti-catabolic effects, and there is bone loss over time after therapy discontinuation. Further, the cellular source of sclerostin in the bone/bone marrow microenvironment under physiological and pathological conditions, the pathways that regulate sclerostin expression and the mechanisms by which sclerostin modulates the activity of osteocytes, osteoblasts, and osteoclasts remain unclear. In this review, we highlight the current knowledge on the regulation of Sost/sclerotin expression and its mechanism(s) of action, discuss novel observations regarding its role in signaling pathways activated by hormones and mechanical stimuli in bone, and propose future research needed to understand the full potential of therapeutic interventions that modulate Sost/sclerostin expression.

Keywords: Anabolism; Bone formation; Bone resorption; Glucocorticoids; Multiple myeloma; Osteocytes; PTH; Wnt/βcatenin signaling.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

Authors have no conflicts of interest to report.

Figures

Figure 1. Role and mechanism of action of Sost/sclerostin in bone

The expression of Sost/sclerostin is tightly regulated by complex mechanisms involving crosstalk between systemic hormones, cytokines and mechanical stimuli (black lines). The chaperone LRP4 presents sclerostin to the Wnt co-receptors LRP5/6, thus facilitating sclerostin inhibition of Wnt/βcatenin signaling. The consequent inhibition of the Wnt/βcatenin pathway leads to decreased bone formation due to impaired osteoblastogenesis and decreased osteoblast survival (green line). Novel findings suggest that activation of osteocytic Wnt/βcatenin signaling itself increases the expression of Sost/sclerostin, which in turn acts in a negative feedback limiting bone formation driven by the pathway. Sclerostin not only regulates bone formation, but also bone resorption (blue lines). Inhibition of Wnt/βcatenin signaling in osteoblasts and osteocytes decreases the expression of Opg, and direct actions of sclerostin on osteocytes increase the expression of RANKL. In addition, inhibition of Wnt/βcatenin signaling in osteoclast precursors directly favors their differentiation. Thus, by antagonizing Wnt/βcatenin signaling, sclerostin has the potential to stimulate osteoclast differentiation and enhance bone resorption. Further, sclerostin increases in osteocytes the expression and activity of enzymes that remodel perilacunar matrix leading to osteolytic osteolysis.

Cited by

Sclerostin Regulation, Microarchitecture, and Advanced Glycation End-Products in the Bone of Elderly Women With Type 2 Diabetes.

Piccoli A, Cannata F, Strollo R, Pedone C, Leanza G, Russo F, Greto V, Isgrò C, Quattrocchi CC, Massaroni C, Silvestri S, Vadalà G, Bisogno T, Denaro V, Pozzilli P, Tang SY, Silva MJ, Conte C, Papalia R, Maccarrone M, Napoli N. Piccoli A, et al. J Bone Miner Res. 2020 Dec;35(12):2415-2422. doi: 10.1002/jbmr.4153. Epub 2020 Oct 2. J Bone Miner Res. 2020. PMID: 32777114 Free PMC article.

Wnt pathway in bone: knowledge structure and hot spots from 1993 to 2022.

Liu T, Zhao J, Zhang X, Wang Y, Wang W, Song J. Liu T, et al. Front Physiol. 2023 Nov 16;14:1279423. doi: 10.3389/fphys.2023.1279423. eCollection 2023. Front Physiol. 2023. PMID: 38033331 Free PMC article.

The cytoskeleton and connected elements in bone cell mechano-transduction.

Gould NR, Torre OM, Leser JM, Stains JP. Gould NR, et al. Bone. 2021 Aug;149:115971. doi: 10.1016/j.bone.2021.115971. Epub 2021 Apr 21. Bone. 2021. PMID: 33892173 Free PMC article. Review.

Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations.

Xie J, Guo J, Kanwal Z, Wu M, Lv X, Ibrahim NA, Li P, Buabeid MA, Arafa EA, Sun Q. Xie J, et al. Int J Endocrinol. 2020 Sep 10;2020:3236828. doi: 10.1155/2020/3236828. eCollection 2020. Int J Endocrinol. 2020. PMID: 32963524 Free PMC article. Review.

Bone Diseases in Patients with Chronic Liver Disease.

Jeong HM, Kim DJ. Jeong HM, et al. Int J Mol Sci. 2019 Aug 31;20(17):4270. doi: 10.3390/ijms20174270. Int J Mol Sci. 2019. PMID: 31480433 Free PMC article. Review.

References

Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2):179–192. - PubMed Gori F, Lerner U, Ohlsson C, Baron R. A new WNT on the bone: WNT16, cortical bone thickness, porosity and fractures. Bonekey Rep. 2015;4:669. - PMC - PubMed Poole KE, Van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19(13):1842–1844. - PubMed Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280(20):19883–19887. - PubMed Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011;286(22):19489–19500. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

R01 CA209882/CA/NCI NIH HHS/United States IK6 BX004596/BX/BLRD VA/United States R01 DK076007/DK/NIDDK NIH HHS/United States I01 BX002104/BX/BLRD VA/United States R01 AR059357/AR/NIAMS NIH HHS/United States S10 RR023710/RR/NCRR NIH HHS/United States T32 AR065971/AR/NIAMS NIH HHS/United States